Compare Cassava Sciences Inc (FLNA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs J M Smucker Co — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while J M Smucker Co trades at $118.79 (market cap $12.54B). The key difference: J M Smucker Co is far larger — about 262.6× Cassava Sciences Inc's market cap, and J M Smucker Co pays a 3.82% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SJM | |
|---|---|---|
Market Cap | $47.75M | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $126.35 |
52-Week Low | $0.87 | $89.53 |
Enterprise Value | -$34.93M | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
SJM trades at $118.07, down 1.74% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported mixed fundamentals with strong revenue growth to $8.73B in 2025 but negative net income of -$1.23B. Recent dividend increases and positive earnings beats in Q4 2025 and Q1 2026 highlight management's confidence amid profitability challenges.
Wall Street maintains a cautiously optimistic outlook with 52% analyst buy ratings and a $125.11 consensus target, representing 6% upside. Key risks include persistent negative margins and high debt levels, while opportunities lie in cost controls and Uncrustables growth. The stock offers value at reasonable P/S and P/B multiples with dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
